The TP53 mutation also showed better prognosis in metaplastic breast cancer, as it was correlated with better recurrence-free survival (RFS, p = 0.03) and OS (p = 0.06) compared to mutations in the PI3K/Akt/mTOR pathway [43]. This evidence concerns the gene MTOR and breast cancer.